Evidence map›Paper›PMID 39006421›Full record

ArticlemedRxiv : the preprint server for health sciences2024

A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests.

Noëlle Warmenhoven, Gemma Salvadó, Shorena Janelidze, Niklas Mattsson-Carlgren, Divya Bali, Anna Orduña Dolado, Hartmuth Kolb, Gallen Triana-Baltzer, Nicolas R Barthélemy, Suzanne E Schindler and 14 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Noëlle WarmenhovenClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.ORCID 0009-0003-0557-5102
Gemma SalvadóClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Shorena JanelidzeClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Niklas Mattsson-CarlgrenClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Divya BaliClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Anna Orduña DoladoClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Hartmuth KolbNeuroscience Biomarkers, Johnson and Johnson Innovative Medicine, San Diego, CA, USA.
Gallen Triana-BaltzerNeuroscience Biomarkers, Johnson and Johnson Innovative Medicine, San Diego, CA, USA.
Nicolas R BarthélemyThe Tracy Family SILQ Center, Washington University School of Medicine, St. Louis, MO, USA.
Suzanne E SchindlerDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Andrew J AschenbrennerDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Cyrus A RajiKnight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Tammie L S BenzingerKnight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
John C MorrisDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Laura IbanezDepartment of Psychiatry, Washington University, St. Louis, MO, USA.ORCID 0000-0003-2381-7059
Jigyasha TimsinaDepartment of Psychiatry, Washington University, St. Louis, MO, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University, St. Louis, MO, USA.ORCID 0000-0002-0276-2899
Randall J BatemanThe Tracy Family SILQ Center, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-7729-1702
Nicholas AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Burak ArslanDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Alexa Pichet BinetteClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.

Funding

Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
Staging Alzheimer disease with blood-based biomarkersR01AG070941 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2021 to 2025
$4.3M
USING QUANTITATIVE TRAITS TO IDENTIFY NOVEL GENES FOR ALZHEIMERS DISEASE AND OTHER COMPLEX TRAITSRF1AG053303 · NIA · WASHINGTON UNIVERSITY · PI CLIMER, SHARLEE, CRUCHAGA, CARLOS · 2016 to 2020
$4.0M
GENETIC MODIFIERS OF CEREBROSPINAL FLUID TREM2 IN ALZHEIMER'S DISEASERF1AG058501 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, PICCIO, LAURA · 2018 to 2018
$3.5M
The Familial Alzheimer Sequencing (FASe) ProjectU01AG058922 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS, GOATE, ALISON M · 2018 to 2022
$3.5M
Sex-specific Molecular Profiling to Understand Pathology and Identify Causal Genes and Drug Targets for Alzheimer's DiseaseRF1AG074007 · NIA · WASHINGTON UNIVERSITY · PI SUNG, YUNJU · 2021 to 2021
$2.7M
IDENTIFYING RARE VARIANTS THAT INCREASE RISK FOR ALZHEIMER'S DISEASER01AG044546 · NIA · WASHINGTON UNIVERSITY · PI CRUCHAGA, CARLOS · 2013 to 2017
$2.7M
Prospective validation and implementation of high-performing blood biomarkers and digital cognitive tests for detection of Alzheimer's disease in specialist memory clinic and primary care settingsR01AG083740 · NIA · LUNDS UNIVERSITET · PI Sebastian Palmqvist · 2023 to 2026
$1.9M
NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS R01 AG044546NIA NIH HHS R01 AG070941NIA NIH HHS R01 AG083740NIA NIH HHS RF1 AG053303NIA NIH HHS RF1 AG058501NIA NIH HHS RF1 AG074007NIA NIH HHS U01 AG058922
6 · The paper itself

Abstract

Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarkers for reliable detection of Alzheimer's disease (AD) pathology. Various p-tau217 assays have been developed, but their relative performance is unclear. We compared key plasma p-tau217 tests using cross-sectional and longitudinal measures of amyloid-β (Aβ)-PET, tau-PET, and cognition as outcomes, and benchmarked them against cerebrospinal fluid (CSF) biomarker tests. Samples from 998 individuals (mean[range] age 68.5[20.0-92.5], 53% female) from the Swedish BioFINDER-2 cohort were analyzed. Plasma p-tau217 was measured with mass spectrometry (MS) assays (the ratio between phosphorylated and non-phosphorylated [%p-tau217

Indexed as

Alzheimer’s diseaseCSF biomarkersplasma biomarkersp-tau217

Identifiers

PMID39006421
PMCPMC11245081

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.